Curated News
By: NewsRamp Editorial Staff
May 08, 2024
ANGLE PLC announces supplier agreement with AstraZeneca for prostate cancer assay
TLDR
- ANGLE PLC's supplier agreement with AstraZeneca PLC is set to enhance prostate cancer studies, giving ANGLE a competitive edge.
- The agreement aims to develop an androgen receptor (AR) detection assay using ANGLE's Parsortix system, scheduled for completion in the first quarter of next year.
- Successful development of the AR assay is expected to improve clinical oncology and assess the efficacy of prostate cancer therapies, contributing to a better future for cancer patients.
- The supplier agreement between ANGLE PLC and AstraZeneca PLC is a significant step forward in the field of prostate cancer studies and oncology research.
Impact - Why it Matters
The partnership between ANGLE PLC and AstraZeneca to develop the AR detection assay is significant for the advancement of prostate cancer studies and clinical oncology. This innovative development has the potential to improve the assessment of prostate cancer therapies, ultimately impacting patient care and treatment outcomes.
Summary
ANGLE PLC CEO Andrew Newland has announced a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay for prostate cancer studies. The project, valued at £550,000, is set for completion in Q1 of next year. This innovative development is expected to enhance ANGLE's market position and operations, particularly in clinical oncology for assessing the efficacy of prostate cancer therapies.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, ANGLE PLC announces supplier agreement with AstraZeneca for prostate cancer assay
